$24.6 million for Australian clinical trials hub at Alfred to focus on regional cancer trials

The Liberal National Government is providing almost $25 million so Australians with cancer and rare diseases have access to clinical trials no matter where they live including regional and remote Victoria.

Patients with poor access to clinical trial programs don’t always gain early access to breakthroughs in medical treatment that can be life-saving.

Our Government will provide funding support to the Australian Clinical Trials Network’s TrialHub.

This will boost opportunities for patients across Australia to participate in clinical trials of new treatments and other interventions as close as possible to their homes, regardless of where they live.

The program will create partnerships with regional hospitals to expand the reach and participation in clinical trials, allowing patients from all over Victoria access to potentially life-saving treatments.

Hospitals in Rosebud, Casey and Bendigo in Victoria will be the first hospitals to partner with the TrialHub.

TrialHub’s initial focus will be on rare cancers and other rare diseases, prostate cancer and melanoma.

This program is a collaboration between Monash University and Alfred Health to boost the number of available clinical trials in Victoria.

Clinical trials are the vehicles through which advances in medical science are translated to the benefit of patients and their communities, providing essential conduits from scientific discovery to improved health outcomes for all.

This investment is through our Government’s Community Health and Hospitals Program.

Established in 2018, the Liberal National Government’s $1.25 billion Community Health and Hospitals Fund supports:

    • Specialist hospital services such as cancer treatment, rural health and hospital infrastructure
    • Drug and alcohol treatment
    • Preventive, primary and chronic disease management
    • Mental health

/Media Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.